Search

Displaying results 6791 - 6800 of 7041 in total
  1. Drug

    Sar9, Met (O2)11-Substance P

    go.drugbank.com/drugs/DB05875
    Investigational

    Sar9, Met (O2)11-Substance P is a neurokinin-1 receptor agonist. It is an analog of the naturally occurring human neuropeptide Substance P, which can be found throughout the body, including in the airways of humans and many other species.

  2. Drug

    CHGN111

    go.drugbank.com/drugs/DB06376
    Experimental

    CHGN111 is an inhibitor of the mitochondrial enzyme CLK-1 which is a demethoxyubiquinone hydroxylase. Numerous parameters of mitochondrial function are altered when the activity of CLK-1 is reduced, which results in a decrease of ROS at ...

  3. Drug

    Piboserod

    go.drugbank.com/drugs/DB04873
    Investigational

    Piboserod (SB 207266) is a selective 5-HT(4) receptor antagonist.

  4. Drug

    Nangibotide

    go.drugbank.com/drugs/DB16247
    Investigational

    Nangibotide is under investigation in clinical trial NCT04055909 (Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock).

  5. Drug

    PPL-100

    go.drugbank.com/drugs/DB05961
    Investigational

  6. Drug

    Aldoxorubicin

    go.drugbank.com/drugs/DB06013
    Investigational

    Aldoxorubicin, an antineoplastic agents, is an albumin-binding prodrug of doxorubicin.

  7. Drug

    MLN2222

    go.drugbank.com/drugs/DB06503
    Experimental

    MLN2222 is a novel, proprietary recombinant protein that blocks both the C3 and C5 convertases, which are essential components of the complement activation pathway.

  8. Drug

    N-(2-Aminoethyl)-1-aziridineethanamine

    go.drugbank.com/drugs/DB15643
    Experimental

    First described in the literature in 2004, N-(2-Aminoethyl)-1-aziridineethanamine is an experimental angiotensin converting enzyme 2 inhibitor investigated for its use in treating cardiovascular disease and its activity against Severe Ac...

  9. Drug

    TM5614

    go.drugbank.com/drugs/DB16516
    Investigational

    TM5614 is a novel, orally active, plasminogen activator inhibitor 1 (PAI-1) inhibitor[A228788,A228793,]. PAI-1 is a marker of obesity, type 2 diabetes, and metabolic syndrome , and current studies are exploring downstream effects of its ...

  10. Drug

    Varlitinib

    go.drugbank.com/drugs/DB05944
    Investigational

    Varlitinib is an oral, selective, reversible, small molecule tyrosine kinase inhibitor of both ErbB-2 (Her-2/neu) and EGFR. Over-expression of ErbB-2 and EGFR receptors in tumors is predictive of poor prognosis in cancer patients. Varlit...